Are you Dr. Tempero?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1600 Divisadero St
San Francisco, CA 94143Phone+1 415-353-9888Fax+1 415-353-7150
Summary
- Dr. Margaret Tempero, MD is an oncologist in San Francisco, California. She is currently licensed to practice medicine in California, Iowa, and Nebraska. She is affiliated with UCSF Medical Center, Zuckerberg San Francisco General Hospital and Trauma Center, and San Francisco VA Medical Center.
Education & Training
University of Nebraska Medical Center College of MedicineFellowship, Hematology and Medical Oncology, 1982 - 1982- University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1977 - 1980
University of Nebraska College of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 2000 - 2025
NE State Medical License 1978 - 2016
IA State Medical License 1985 - 1999- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer Start of enrollment: 1998 Sep 01
- Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer Start of enrollment: 2001 Apr 01
- A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer Start of enrollment: 2009 May 01
Publications & Presentations
PubMed
- Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.Phoebe N Miller, Fernanda Romero-Hernandez, Lucia Calthorpe, Jaeyun Jane Wang, Sunhee S Kim
Annals of Surgical Oncology. 2024-09-01 - ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.Phoebe N Miller, Fernanda Romero-Hernandez, Lucia Calthorpe, Jaeyun Jane Wang, Sunhee S Kim
Annals of Surgical Oncology. 2024-07-27 - 17 citationsAmpullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.E Gabriela Chiorean, Marco Del Chiaro, Margaret A Tempero, Mokenge P Malafa, Al B Benson
Journal of the National Comprehensive Cancer Network. 2023-07-01
Press Mentions
JCO Article Insights: Use of Independently-Assessed vs Investigator-Assessed DFS in the APACT TrialMay 15th, 2023- New Advisory Board Chair Has Been Part of PanCAN Since the BeginningJuly 7th, 2021
- The Pancreatic Cancer Action Network (PanCAN) Welcomes Two New Board Members and Scientific and Medical Advisory Board ChairJuly 6th, 2021
- Join now to see all
Grant Support
- Clinical Research Support ServicesNational Cancer Institute2007–2011
- Mechanism-Based Evaluations Of Erbb-Targeted AgentsNational Cancer Institute2002–2006
- Optimizing Radioimmunotherapy For Pancreatic CancerNational Cancer Institute1997–2002
- Mechanism Based Evaluations Of ERBB Targeted AgentsNational Cancer Institute2001
- Spore In Gastointestinal CancerNational Cancer Institute1997–1999
- Unmc/Eppley Cancer Center Support GrantNational Cancer Institute1997–1998
- Defining Toxicity And Benefit For RadioimmunotherapyNational Cancer Institute1993–1995
Professional Memberships
- Fellow
